COVID-19 Study of Safety and Tolerability of Alvelestat

  • days left to enroll
  • participants needed
  • sponsor
    University of Alabama at Birmingham
Updated on 9 May 2021


The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK), and explore the mechanistic and clinical effect of alvelestat (an oral neutrophil elastase inhibitor) orally twice per day for 10 days added to standard of care in adult patients (18 years) with COVID-19 respiratory disease.

Condition COVID19
Treatment Placebo, Alvelestat
Clinical Study IdentifierNCT04539795
SponsorUniversity of Alabama at Birmingham
Last Modified on9 May 2021


Yes No Not Sure

Inclusion Criteria

Male or Female
Age 18 years
Proven SARS-Cov-2 infection (confirmed by PCR from a nasopharyngeal or lower respiratory tract sample)
A score of Grade 3 to 5 on the WHO 9-point Ordinal Scale
Male participants must agree to use a highly effective contraception during the treatment period and for at least 4 days after the last dose of study treatment and refrain from donating sperm during this period
Female participants are eligible to participate if not pregnant; not breastfeeding; and at least one of the following conditions is met
Not a woman of childbearing potential OR A woman of childbearing potential who
agrees to follow the contraceptive guidance during the treatment phase and for
at least 4 days after the last dose of study medication - Capable of giving
signed informed consent which includes a commitment to comply with the
requirements and restrictions listed in the informed consent form (ICF) and
within this protocol

Exclusion Criteria

Patients who have previously had a score of 6 or 7 on the WHO 9-point Ordinal Scale
Patients who require support with invasive mechanical ventilation at the time of inclusion, or expected to be required within 24 hours of randomization
Alanine aminotransferase (ALT) OR aspartate aminotransferase (AST) >2 the upper limit of normal (ULN) OR Total Bilirubin > ULN. In patients with a documented history of Gilbert's Syndrome AND baseline total bilirubin elevation consistent with an exacerbation of Gilbert's Syndrome (i.e. no other cause of total bilirubin elevation), subjects may enroll if total bilirubin is < 5x ULN
Diagnosis of liver cirrhosis, esophageal varices, ascites or hepatic encephalopathy
Chronic liver diseases such as autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, haemochromatosis
Significant renal disease or infection (as determined by the Investigator) including stage 4 chronic kidney disease or estimated glomerular filtration rate <60mL/min
Absolute neutrophil count 1000/L at screening
Myocardial infarction, transient ischemic attack or stroke within 3 months prior to the first dose
Current unstable angina or congestive heart failure (New York Heart Association III/IV)
Screening 12-lead EKG with a measurable QTc interval according to Fridericia correction (QTcF) >450 ms
Anticipated transfer to another hospital that is not the study center within 24 hours
Allergy to study medication or excipients
Inability to swallow tablets
Other documented comorbidities or laboratory abnormalities that in the opinion of the Investigator could affect the outcome of the study assessments, participant safety, or ability of the participant to comply with the requirements of the protocol
Any patient whose interests are not best served by study participation, as determined by the Investigator
Excluded Prior/Concomitant Therapy
Requirement for medications mainly metabolized by CYP2C9 and with narrow therapeutic index (eg, warfarin, phenytoin) is prohibited unless therapeutic monitoring available for duration of alvelestat dosing
Medicines that are potent CYP3A4 inhibitors including (but are not limited to) clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, ritonavir, verapamil and potent inducers including but not limited to phenobarbital, phenytoin and rifampicin, will be exclusionary
Requirement for medications substantially reliant on OATP1B1 for metabolism where discontinuation during study drug administration is not possible or where fluctuations in levels are considered clinically important (as per investigator judgement) and cannot be clinically monitored (e.g., statins, valsartan, olmesartan, enalapril, repaglinide)
Excluded Prior/Concurrent Clinical Study Experience
Participation in any clinical investigation using investigational treatments within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to the initial dosing (or longer if required by local regulations) is prohibited. Use of remdesivir (Veklury) under the conditions of the authorization for emergency use in the US, and per manufacturer's instructions, is permitted
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note